A high eosinophil level, for example, can indicate a range of several health conditions, from allergic reactions and asthma ...

A deep-dive analysis of preschoolers' lungs can help pediatricians identify potential cases of asthma and responsiveness to ...

The phase IIIA trials randomized 792 patients ages 12 and older with severe asthma in a 2:1 ratio to depemokimab (100 mg ...

Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, shares findings from the FLAME trial on blood eosinophil changes in patients with chronic ...

Eosinophilic asthma (also known as e-asthma or eos asthma) is a severe form of asthma that causes high levels of eosinophils in the lung tissue, blood, and mucus. Eosinophils are a type of immune ...

This investigational trial will evaluate the effects of three dose levels of oral dexpramipexole for 12 weeks on peripheral blood eosinophil count, lung function, and asthma control. Additionally ...

The modern debate over ICSs in COPD has the catnip required to produce an academic catfight. It pits "statements" against ...

Researchers assess the airway microbiome and host immune-inflammatory responses to identify treatable aspects of severe ...

British drugmaker GSK said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating ...

et al. Additive prognostic value of blood eosinophils and exhaled nitric oxide (FeNO) to predict asthma attacks in the ORACLE patient-level meta-analysis. ERS 2024. Poster ID 1205.

GSK’s depemokimab, a new ultra-long-acting biologic, showed a 54% reduction in severe asthma exacerbations in the SWIFT-1 and ...